Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-17-005580
Filing Date
2017-05-15
Accepted
2017-05-15 16:59:14
Documents
47
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q Q1 2017 q1201710q.htm 10-Q 537905
2 EXHIBIT 31.1 Q1 2017 q12017-exhibit311.htm EX-31.1 16033
3 EXHIBIT 31.2 q12017-exhibit312.htm EX-31.2 16034
4 EXHIBIT 32.1 Q1 2017 q12017-exhibit321.htm EX-32.1 8336
  Complete submission text file 0001628280-17-005580.txt   2416796

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cpix-20170331.xml EX-101.INS 325394
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20170331.xsd EX-101.SCH 22509
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20170331_cal.xml EX-101.CAL 48299
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20170331_def.xml EX-101.DEF 78092
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20170331_lab.xml EX-101.LAB 295284
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20170331_pre.xml EX-101.PRE 166236
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 10-Q | Act: 34 | File No.: 001-33637 | Film No.: 17845383
SIC: 2834 Pharmaceutical Preparations